GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Starry Pharmaceutical Co Ltd (SHSE:603520) » Definitions » Ending Cash Position

Zhejiang Starry Pharmaceutical Co (SHSE:603520) Ending Cash Position : ¥488 Mil (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Zhejiang Starry Pharmaceutical Co Ending Cash Position?

Zhejiang Starry Pharmaceutical Co's Ending Cash Position for the quarter that ended in Sep. 2024 was ¥488 Mil.

Zhejiang Starry Pharmaceutical Co's quarterly Ending Cash Position increased from Mar. 2024 (¥462 Mil) to Jun. 2024 (¥1,069 Mil) but then declined from Jun. 2024 (¥1,069 Mil) to Sep. 2024 (¥488 Mil).

Zhejiang Starry Pharmaceutical Co's annual Ending Cash Position declined from Dec. 2021 (¥614 Mil) to Dec. 2022 (¥579 Mil) and declined from Dec. 2022 (¥579 Mil) to Dec. 2023 (¥453 Mil).

Zhejiang Starry Pharmaceutical Co Ending Cash Position Historical Data

The historical data trend for Zhejiang Starry Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Starry Pharmaceutical Co Ending Cash Position Chart

Zhejiang Starry Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 294.28 689.26 614.26 578.76 453.16

Zhejiang Starry Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 685.71 453.16 462.37 1,069.47 488.14

Zhejiang Starry Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Zhejiang Starry Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=578.765+-125.608
=453

Zhejiang Starry Pharmaceutical Co's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1069.467+-581.33
=488

Zhejiang Starry Pharmaceutical Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Zhejiang Starry Pharmaceutical Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang Starry Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Starry Pharmaceutical Co Ltd (SHSE:603520) » Definitions » Ending Cash Position
Comparable Companies
SZSE:301089 SZSE:000931 SHSE:688221 SZSE:300239 SHSE:603669 SZSE:002688 SZSE:000788 SHSE:688176 SZSE:301277 SZSE:300485 ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA NSE:DIVISLAB XSWX:SDZ VTRS
Traded in Other Exchanges
N/A
Address
No.1 Sitali Avenue, Modern Industrial Gathering District, Zhejiang Province, Xianju County, Taizhou City, CHN, 317306
Website
http://www.starrypharm.com
Zhejiang Starry Pharmaceutical Co Ltd is engaged in R&D, manufacture and marketing of active ingredient and intermediate X-CT non-ionic contrast agent series and Fluoroquinolones series.
Executives
Hu Jin Sheng Director

Zhejiang Starry Pharmaceutical Co Headlines

No Headlines